vimarsana.com

Page 142 - வடமேற்கு பல்கலைக்கழகம் ஃபைன்பெர்க் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Longeveron Inc Announces the Appointment of Prominent Biotech, Capital Markets and Corporate

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Longeveron Inc. Announces the Appointment of Prominent Biotech, Capital Markets and Corporate . LongeveronFebruary 18, 2021 GMT MIAMI, Feb. 18, 2021 (GLOBE NEWSWIRE) Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and life-threatening conditions, today announced the appointments of Douglas Losordo, M.D., Erin Borger, and Cathy Ross to the Company’s Board of Directors. Douglas Losordo, MD Dr. Losordo has worked in the biotech industry for over twenty years, most recently serving as Executive Vice President, Head of Research and Development and Chief Medical Officer of KBP Biosciences Inc. Dr. Losordo was previously the Executive Vice President, Global Head of Research and Development, Chief Medical Officer of Caladrius Biosciences (Nasdaq: CLBS), a clinical-stage bio

Chutes & Ladders—Zimmer Biomet calls on Medtronic vet Jamali to lead spinout

Samir Mody as chief commercial officer, while  Friedrich Asmus signs on as SVP, clinical development and medical affairs. Meanwhile, the company has also tapped  Joel Centeno as SVP, manufacturing, quality and supply chain. Mody comes over from Medtronic, where he was vice president, CRHF strategy, health economics and reimbursement. Asmus previously served as VP of clinical development at ophthalmology biotech ProQR Therapeutics, while Centeno comes over after stints at Boston Scientific, Hologic and AltheaDx. > Antios Therapeutics has tapped  Tamra Adams as chief financial officer, a newly created executive position at the company. Before joining Antios, Adams founded Accounting Concepts, which provided CFO, accounting, and financial services to emerging growth companies in the biopharmaceutical and information technology industries, including Engage Therapeutics.

We re Not Here to Steal Jobs — Immigration Agency s Delays Jeopardize International Students Legal Status – NBC10 Philadelphia

The delays constitute another challenge to the country’s ability to recruit and retain highly educated, highly skilled students and workers from abroad.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.